Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis

European Respiratory Journal

Volumn 41, Issue 3, 2013, Pages 656-663

  Gottschling, Sandra ^a   Jensen, Katrin ^b   Warth, Arne ^b   Herth, Felix J F ^a   Thomas, Michael ^a   Schnabel, Philipp A ^b   Herpel, Esther ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Basaloid nonsmall cell lung cancer; Biomarker; Prognosis; Stage specific embryonic antigen 4

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN 1; PROTEIN; STAGE SPECIFIC EMBRYO ANTIGEN 4; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BASAL CELL CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL;

AGED; ANTIGENS, CD; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; STAGE-SPECIFIC EMBRYONIC ANTIGENS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875261402     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00225711     Document Type: Article

References (44)

1. Moro-Sibilot D, Lantuejoul S, Diab S, et al. Lung carcinomas with a basaloid pattern: A study of 90 cases focusing on their poor prognosis. Eur Respir J 2008; 31: 854-859.
2. Kim DJ, Kim KD, Shin DH, et al. Basaloid carcinoma of the lung: A really dismal histologic variant?Ann Thorac Surg 2003; 76: 1833-1837.
3. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009; 136: 260-271.
4. Pfannschmidt J, Muley T, Bulzebruck H, et al. Prognostic assessment after surgical resection for non-small cell lung cancer: Experiences in 2083 patients. Lung Cancer 2007; 55: 371-377.
5. Brambilla E, Moro D, Veale D, et al. Basal cell carcinoma (basaloid) carcinoma with separate prognostic significance. Hum Pathol 1992; 23: 993-1003.
6. Moro D, Brichon P-Y, Brambilla E, et al. Basaloid bronchial carcinoma. A histologic group with a poor prognosis. Cancer 1994; 73: 2734-2739.
7. Marci V, Volante M, Cappia S, et al. Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma. Virchows Arch 2007; 451: 729-736.
8. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Diff 2008; 15: 504-514.
9. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009; 106: 16281-16286.
10. Kajstura J, Rota M, Hall SR, et al. Evidence for human lung stem cells. NEJM 2011; 364: 1795-1806.
11. Li F, Zeng H, Ying K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 2011; 28: 1458-1462.
12. Woo T, Okudela K, Mitsui H, et al. Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 2010; 4: 32-42.
13. The International Stem Cell Initiative. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nature Biotech 2007; 25: 803-816.
14. Levina V, Marrangoni AM, DeMarco R, et al. Drug-selected human lung cancer stem cells: Cytokine network, tumorigenic and metastatic properties. PLoS ONE 2008; 3: E3077.
15. Chen Y-C, Hsu H-S, Chen Y-W, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 2008; 3: E2637.
16. Karoubi G, Gugger M, Schmid R, et al. OCT4 expression in human non-small cell lung cancer: Implications for therapeutic intervention. Interact Cardiovasc Thorac Surg 2009; 8: 393-397.
17. Zhang X, Han B, Huang J, et al. Prognostic significance of OCT4 expression in adenocarcinoma of the lung. Jpn J Clin Oncol 2010; 40: 961-966.
18. Krupnik JG, Damjanov I, Damjanov A, et al. Globo-series carbohydrate antigens are expressed in different forms of human and murine teratocarcinoma-derived cells. Int J Cancer 1994; 59: 692-698.
19. Tokuyama S, Saito S, Takahashi T, et al. Immunostaining of stagespecific embryonic antigen-4 in intratubular germ cell neoplasia unclassified and in testicular germ-cell tumors. Oncol Rep 2003; 10: 1097-1104.
20. Ye F, Li Y, Hu Y, Zhou C, et al. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma. Int J Gyn Cancer 2010; 20: 958-964.
21. Goeckenjan G, Sitter H, Thomas M, et al. Prevention, diagnosis, therapy, and follow-up of lung cancer. Pneumologie 2010; 64: Suppl. 2, e1-e164.
22. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, International Agency for Research on Cancer, 2004.
23. Warth A, Muley T, Meister M, et al. The novel histologic IASLC/ATS/ERS classification system of invasive pulmonary adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012; 30: 1438-1446.
24. Draper JS, Pigott C, Thomson JA, et al. Surface antigens of human embryonic stem cells: Changes upon differentiation in culture. J Anat 2002; 200: 249-258.
25. Gottschling S, Jauch A, Kuner R, et al. Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue. Lung Cancer 2012; 75: 45-57.
26. Fukuoka K, Narita N, Saijo N. Increased expression of sialyl Lewis(x) antigen is associated with distant metastasis in lung cancer patients: Immunohistochemical study on bronchofiberscopic biopsy specimens. Lung Cancer 1998; 20: 109-116.
27. Ogawa J, Sano A, Inoue H, et al. Expression of Lewis-related antigen and prognosis in stage I non-small cell lung cancer. Ann Thorac Surg 1995; 59: 412-415.
28. Wang LC, Wang L, Kwauk S, et al. Analysis on the clinical features of 22 basaloid squamous cell carcinoma of the lung. J Cardiothoracic Surg 2011; 6: 10.
29. Waechter F, Passweg J, Tamm M, et al. Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest 2005; 127: 738-747.
30. Kannagi R, Cochran NA, Ishigami F, et al. Stage-specific embryonic antigens (SSEA-3 and-4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO 1983; 2: 2355-2361.
31. Josephson R, Ording CJ, Liu Y, et al. Qualification of embryonal carcinoma 2102Ep as a reference for human embryonic stem cell research. Stem Cells 2007; 25: 437-446.
32. Brimble SN, Sherrer ES, Uhl EW, et al. The cell surface glycosphingolipids SSEA-3 and SSEA-4 are not essential for human ESC pluripotency. Stem Cells 2007; 25: 54-62.
33. Reubinoff BE, Pera MF, Fong C-Y, et al. Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. Nature Biotech 2000; 18: 399-404.
34. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
35. Karlsson C, Bodin L, Piehl-Aulin K, et al. Tissue microarray validation: A methodologic study with special reference to lung cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2014-2021.
36. Kao SC, Lee K, Armstrong NJ, et al. Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology 2011; 43: 128-132.
37. Schmidt LH, Biesterfeld S, Kummel A, et al. Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res 2009; 29: 201-209.
38. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
39. Kim J, Woo AJ, Chu J, et al. A Myc rather than core pluripotency module accounts for the shared signature of embryonic stem and cancer cells. Cell 2010; 143: 313-324.
40. Gazzeri S, Brambilla E, Caron de Fromentel C, et al. P53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer 1994; 58: 24-32.
41. Mitani S, Kamata H, Fujiwara M, et al. Analysis of c-myc DNA amplification in non-small cell lung carcinoma in comparison with small cell lung carcinoma using polymerase chain reaction. Clin Exp Med 2001; 1: 105-111.
42. Broers JL, Viallet J, Jensen SM, et al. Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol 1993; 9: 33-43.
43. Katagirii YU, Ohmi K, Katagiri C, et al. Prominent immunogenicity of monosialosyl galactosylgloboside, carrying a stage-specific embryonic antigen-4 (SSEA-4) epitope in the ACHN human renal tubular cell line-a simple method for producing monoclonal antibodies against detergent-insolublemicrodomains/raft. Glycoconj J 2001; 18: 347-353.
44. Sullivan JP, Minna JD, Shay JW. Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 2010; 29: 61-72.